SG10201604304RA - Radiolabelled glutaminyl cyclase inhibitors - Google Patents

Radiolabelled glutaminyl cyclase inhibitors

Info

Publication number
SG10201604304RA
SG10201604304RA SG10201604304RA SG10201604304RA SG10201604304RA SG 10201604304R A SG10201604304R A SG 10201604304RA SG 10201604304R A SG10201604304R A SG 10201604304RA SG 10201604304R A SG10201604304R A SG 10201604304RA SG 10201604304R A SG10201604304R A SG 10201604304RA
Authority
SG
Singapore
Prior art keywords
glutaminyl cyclase
cyclase inhibitors
radiolabelled
radiolabelled glutaminyl
inhibitors
Prior art date
Application number
SG10201604304RA
Inventor
Ulrich Heiser
Daniel Ramsbeck
Hans-Ulrich Demuth
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of SG10201604304RA publication Critical patent/SG10201604304RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG10201604304RA 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors SG10201604304RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161490654P 2011-05-27 2011-05-27

Publications (1)

Publication Number Publication Date
SG10201604304RA true SG10201604304RA (en) 2016-07-28

Family

ID=46149465

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013081567A SG194770A1 (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors
SG10201604304RA SG10201604304RA (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013081567A SG194770A1 (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors

Country Status (14)

Country Link
US (2) US8945510B2 (en)
EP (1) EP2714098A1 (en)
JP (1) JP2014515364A (en)
KR (1) KR20140028076A (en)
CN (1) CN103561776B (en)
AU (1) AU2012264951A1 (en)
BR (1) BR112013030341A2 (en)
CA (1) CA2835014A1 (en)
EA (1) EA028533B1 (en)
IL (1) IL229187A (en)
MX (1) MX2013013946A (en)
SG (2) SG194770A1 (en)
WO (1) WO2012163773A1 (en)
ZA (1) ZA201308329B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904465C (en) 2013-03-15 2021-07-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN104230778B (en) * 2014-07-14 2017-01-04 大连大学 The synthetic method of β-hydrocarbon oxygen acyl group-gamma-alkyl-N-alkyl-butyrolactam
PL3177612T3 (en) 2014-08-04 2022-08-08 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
US11236103B2 (en) 2018-07-27 2022-02-01 Biotheryx, Inc. Bifunctional compounds
KR102230832B1 (en) * 2019-06-17 2021-03-24 (주) 메디프론디비티 N-substituted thiourea or urea derivatives and pharmaceutical composition for use in preventing or treating glutaminyl cyclase activity related diseases containing the same as an active ingredient
MX2022007265A (en) 2019-12-20 2022-09-09 Nuevolution As Compounds active towards nuclear receptors.
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences Inc Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT712759A (en) 1963-01-09
US5304367A (en) * 1990-11-16 1994-04-19 New York University In vivo brain imaging agent and method for diagnosis of psychiatric disorders
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
KR101099206B1 (en) * 2004-02-05 2011-12-27 프로비오드룩 아게 Novel Inhibitors of Glutaminyl Cyclase
EP2021340B1 (en) 2006-04-21 2014-07-23 The Government Of The United States, As Represented by The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
WO2008055945A1 (en) * 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
NZ590658A (en) * 2008-07-31 2012-07-27 Probiodrug Ag Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases
SG193828A1 (en) * 2008-09-04 2013-10-30 Probiodrug Ag Novel inhibitors
CN102438660A (en) 2009-03-23 2012-05-02 美国西门子医疗解决公司 Imaging agents for detecting neurological disorders
US8486940B2 (en) * 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
EP2545047B9 (en) * 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)

Also Published As

Publication number Publication date
BR112013030341A2 (en) 2016-11-29
SG194770A1 (en) 2013-12-30
US20150104389A1 (en) 2015-04-16
US9610368B2 (en) 2017-04-04
MX2013013946A (en) 2014-01-31
IL229187A0 (en) 2013-12-31
US20120301398A1 (en) 2012-11-29
IL229187A (en) 2017-04-30
WO2012163773A1 (en) 2012-12-06
AU2012264951A1 (en) 2013-12-12
JP2014515364A (en) 2014-06-30
NZ617581A (en) 2016-03-31
EP2714098A1 (en) 2014-04-09
ZA201308329B (en) 2015-02-25
EA201301334A1 (en) 2014-05-30
EA028533B1 (en) 2017-11-30
KR20140028076A (en) 2014-03-07
US8945510B2 (en) 2015-02-03
CN103561776A (en) 2014-02-05
CA2835014A1 (en) 2012-12-06
CN103561776B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
HK1202879A1 (en) Compositions and methods for using csf1r inhibitors csf1r
HK1199644A1 (en) Heterocyclylamines as pi3k inhibitors pi3k
HK1200828A1 (en) Kinase inhibitors
ZA201308329B (en) Radiolabelled glutaminyl cyclase inhibitors
ZA201307016B (en) Glucosylceramide synthase inhibitors
EP2683693A4 (en) Rorgammat inhibitors
EP2710007A4 (en) Kinase inhibitors
EP2782580A4 (en) Selective kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
IL229028A0 (en) Kinase inhibitors
HK1199873A1 (en) Kinase inhibitors
GB201112157D0 (en) New use of glutaminyl cyclase inhibitors
GB201120474D0 (en) Inhibitors
GB201018597D0 (en) Inhibitors
SG10201602022UA (en) Glucosylceramide synthase inhibitors